Nanoform

Inside information made public: Nanoform Granted European Commercial cGMP Manufacturing License

Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced that it has received a Commercial cGMP Manufacturing License from FIMEA (Finnish Medicines Agency) for the production and quality control of nanoformed small molecule APIs (Active Pharmaceutical Ingredients). This license authorizes Nanoform to manufacture nanoformed APIs for the European market and for...

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

5 January 2024 -- Helsinki, Finland -- Nanoform Finland, the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative to an amorphous solid dispersion (ASD) formulation of nanoenzalutamide and Xtandi, the number one prescribed androgen receptor...
Cultivator II, Viikinkaari 4 FI-00790 Helsinki, Finland

+358 29 370 0150